Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
D000595:Amino Acid Sequence; D000818:Animals; D004195:Disease Models, Animal; D004357:Drug Synergism; D004789:Enzyme Activation; D005337:Fibrin / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007700:Kinetics; D010958:Plasminogen / Q000378:metabolism; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011487:Protein Conformation; D013379:Substrate Specificity; D013923:Thromboembolism / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D005337:Fibrin; D010958:Plasminogen; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator